Powering the therapeutic ecosystem

23 December 2020

Aquisition by Perkinelmer, inc

Please click the link below to access the transaction website and documentation

Horizon is now part of PerkinElmer, Inc.

As of 23 December 2020, Horizon Discovery Group plc became part of
PerkinElmer, Inc. marking the next exciting stage of our development.

We are leveraging our technological expertise to provide cell engineering tools and services to our customers in three key areas of the therapeutics ecosystem:

  • Basic research

    The demand for life science tools designed to understand drug-gene interactions and the genetic basis of disease.

  • Drug discovery and development

    The need to improve the efficiency and efficacy of drug development by factoring in genetic components to drug development workflows, allowing better choice of targets through a more accurate choice of clinical trial cohort and improved probability of success of a clinical trial and eventual product approval.

  • Therapeutic applications

    The demand for tools to enable production of new therapeutics or better therapeutic approaches, including precision medicines such as cell and gene therapies, and immuno-oncology.

“With the changes we are implementing under our Investing for Growth strategy, Horizon is well positioned to capitalise on its market-leading position.”

terry pizzie,

chief executive officer

Our purpose is to continue to be the world’s leader in designing and engineering genetically modified cells for research/clinical applications that advance human health.

We will do this by being a sustainably profitable business that is driven by customer demand for our market-leading products and services.

  • Expand our tools and services offerings

    Develop and commercialise tools and services that address high-growth end markets: Screening, BioProduction and Base Editing

  • Grow revenues from existing customers and win new customers

    Increase penetration within our target customers and secure larger share of their global budget spend

  • Automate and scale our business

    Drive operational leverage in our business through investment in people, processes and automation

  • Continue to innovate

    Extend our capabilities through both internal R&D as well as inlicensing, partnerships, acquisitions and collaborations

  • People – invest in top talent

    Recruit and retain the talented individuals we need to drive our business forward.

A strong and focused leadership team

Board members come from a broad range of backgrounds and have the depth of skills and experience needed to provide effective guidance to the executive leadership of Horizon as they drive the Group into its profitable growth phase.

Key strengths

Built upon decades of experience in the engineering of cell lines, we have created a unique and high value portfolio of tools and services that support and enable critical elements of the drug development and therapeutic value chain. We believe this expertise forms the basis of a sustainable competitive position.

Featured news

Please click here to see non-regulatory and general company news on Horizon’s main company web site.